. T7-displayed peptides from round 4 in vitro biopanning on TNC-C. 
Supplementary Materials and Methods Cloning, expression, and purification of TNC-C
Vector Construction. A pF1K (Promega, # FXC00319) derivative plasmid containing full-length cDNA of TNC was used for PCR amplification of cDNA region of TNC-C with Phusion Hot Start II High-Fidelity DNA Polymerase (Thermo Fisher Scientific Inc # F-537L; primer pairs: 5′-CTCCTCTCATATGGAGGCCCTGCCCCTTC -3′ and 5′-CAGACACTCGAGTTATCATGTAACAATCTC -3′ for domain TNC-C. NdeI and XhoI restriction sites underlined). The fragments were cloned in the pET28a+ plasmid for TNC-C expression as an N-terminally His-tagged protein.
Expression and purification of TNC-C. The pET28a+TNC-C plasmid was used for transformation of E. coli BL21 Rosetta 2 (DE3) pLysS cells (Novagen, #70956). The protein expression was induced by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) (Sigma, # I6758) to 0.5 mM final concentration and the bacteria were cultured at 18 o C for 16h. Cells were collected by centrifugation, resuspended in ice-cold IMAC buffer (25mM Tris-HCl, 400mM NaCl, 25mM imidazole pH 8, containing EDTA-free protease inhibitor cocktail and DNase I) and lysed by sonification (Bandelin Sonopuls HD 2070, Germany). The cleared bacterial lysate was purified using HiTrap IMAC HP columns (GE Healthcare # 17-0920-05) on ÄKTA purification system (GE Healthcare), and the eluate was dialyzed against PBS using 3.5 kDa cutoff 3mL Slide-A-Lyzer Dialysis Cassettes (Thermo Scientific #66330). TNC-C concentration was determined by bicinchoninic acid assay (Thermo Scientific #23227), and the purity of the proteins was assessed by SDS-PAGE. Mass spectrometry and de novo peptide sequencing were used to confirm the size and sequence of the purified proteins. His-tagged NRP-1 b1b2 domain was expressed and purified as described (Teesalu et al., 2009 ).
Antibody production
Single-chain antibodies: The cDNA sequences encoding TNC-C-G11-scFV were retrieved from US patent application EP2157102 A1, and synthetic DNA fragments were cloned in the pET28a+ expression plasmid. Recombinant antibodies were expressed in E. coli BL21 Rosetta 2 (DE3) pLysS (Novagen, #70956) cells and purified using Protein A GraviTrap Sepharose (GE Healthcare # 28-9852-54), followed by affinity purification on immobilized TNC-C. The purified antibodies were analyzed by SDS-PAGE. Pull-down assays and ELISA were used to verify the interaction of the purified antibodies with the target TNC-C domain.
Clone No. Peptide sequence
Repeats TNC-C binding (fold G7 control phage) Table S1. T7-displayed peptides from round 4 in vitro biopanning on TNC-C. Random phage clones from round 4 of selection on TNC-C were subjected to Sanger sequencing of the peptide-encoding segment of the genome. The table shows peptide sequences of the 38 sequenced clones, and quantitation of binding of individual peptide phages to TNC-C (fold binding of control heptaglycine phage). RGRLXR motif (7 total repeats) is shown in italic, RGRLR motif (18) is underlined, and RLXR motif (12) is indicated in bold. 
Figure. S10. Anti TNC-C antibody validation on surgical explants of human glioma tissues.
The snap-frozen individual patient glioma tissues were sectioned and incubated with the anti-TNC-C mouse antibody (α-TNC-C), or α-TNC-C antibody (10 µg) is pre-incubated of TNC-C protein (60µg) before staining, or only secondary mouse α-alexa647 antibody. The tissue sections were examined by confocal microscopy. The top panel shows α-TNC-C antibody staining. The middle panel shows staining of α-TNC-C antibody is pre-blocked with recombinant TNC-C protein and reveals its specificity. The bottom panel shows secondary antibody staining control. Scale bar, 100 μm for all panels, tissues were stained for the anti-TNC-C mouse (red) and nucleus (DAPI, blue).
Figure. S11. Experimental tumor therapy with PL3-guided NWs extends survival of glioblastoma.
Mice bearing s.c. U87-MG mice were treated with 5 mg/kg of D(KLAKLAK)2-NWs, PL3-NWs, and PL3-D(KLAKLAK)2-NWs, or control PBS (N=6 mice/group). At the endpoint of the study (tumor volume >2000 mm 3 ), the mice were sacrificed by perfusion, and organs and tumors were collected. The mean survival of the different treatment groups was calculated. N = 6 mice/group; Error bars, mean ± SEM; Statistical analyses were performed using paired non-parametric test (Wilcoxon matched-pairs signed-rank test) or Friedman test in GraphPad Prism (*p< 0.05). Fig. S16 . TNC-C and NRP1 receptor expression in U87-MG, PPC1, and M21 cells. The cells grown in coverslip, the cells were stained for TNC-C (green) and NRP1 (green) receptors with FAM-ScFV G11 TNC-C antibody and rabbit α-NRP1 antibody. The nuclei were stained with DAPI(blue). Representative immunofluorescence images from three independent experiments are shown. Scale bars, 20 μm.
Fig. S17. Dequenching of FAM-PL3 upon tryptic digestion of FAM-PL3/TNC-C complex.
The Ni-NTA Magnetic Agarose Beads (QIAGEN, Hilden, Germany) were coated with His-6X tagged TNC-C (300 µg/100 µl beads) at room temperature for 1 h in 400µl of PBS. The TNC-C beads were washed 3 times with washing buffer (PBS, 0.05% NP-40, 1% BSA), followed by incubation with FAM-PL3 peptide (200 µg in 400µl in washing buffer) at room temperature for 2 h. The unbound peptides were removed by rinsing 6 times with washing buffer, and the bound FAM-PL3/TNC-C complex was eluted with 1ml of PBS containing 500mM Imidazole and 0.1% NP40. To measure the dequenching effect, the FAM-PL3/TNC-C complex was treated with trypsin (2.5mg/mL) for 4 h at 37°C. The intensity of fluorescence of the untreated and trypsintreated complex was measured by VICTOR Multilabel Plate Reader (PerkinElmer) at 488/516nm. Student's unpaired two-tailed t-test; the error bars: mean ± SD; ** p ˂ 0.01, N=3. 
